

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 67003

Title: New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HE

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04144629

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: Spain

Manuscript submission date: 2021-04-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-07 19:51

Reviewer performed review: 2021-05-16 22:27

Review time: 9 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The authors summarized the therapeutic advances which target genes uncommonly mutated in NSCLC. However, the info in this review appears not up-to-date. For sample, there are FDA approved therapies for NSCLC harboring BRAF V600E and Ret-fusions, and on 02.17.2021, The FDA granted priority review to sotorasib to treat patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). All these information was not covered in the review. Also BRAF Non-V600 mutations were not covered in the review.